Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males (IX-0106 RBA)

A Randomized, Single-Dose, 3-Way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Caplet Formulation Compared With the IX 01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Caplet Formulation, in Healthy Male Subjects

An open-label, randomized, three-period, three-way crossover trial of single doses of IX-01 in 12 healthy male subjects. In each period, subjects will receive a single oral dose of 1600 mg IX-01, either as an aqueous dispersion in a fasted state, or as caplets in the fed or fasted state

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: IX-01 caplets 1600 mg (4 x 400 mg), fasted; Drug: IX-01 caplets 1600 mg (4 x 400 mg), fed; Drug: IX-01 aqueous dispersion 1600 mg (20 mL), fasted

Detailed Description

This is a Relative Bioavailability Study to compare single oral doses of 1600mg IX-01, either as an aqueous dispersion in a fasted state, or as caplets in the fed or fasted state. Each volunteer in the study will receive each of the formulations listed below. Each formulation will be separated by at least a 5-day drug-free (washout) period.

• Treatment A: A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
• Treatment B: A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
• Treatment C: A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.

In the fasted treatment periods, dosing will follow an overnight fast of at least 10 hours.

In the fed treatment period, following an overnight fast of at least 10 hours, a standard high-calorie, high-fat breakfast meal will be given 30 minutes prior to administration of the study drug.

There will be a final follow-up visit 7-10 days after the final dose of study medication.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78217
      • Worldwide Clinical Trials Early Phase Services, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Body mass index between 18 and 30 kg/m2
• Body weight of ˃60 kg (132 lbs) at screening
• Able to understand the nature of the trial and any hazards of participating. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire trial
• Willing to comply with the contraception requirements of the trial
• Willing to give written consent to participate
• Willing and able to remain in the study unit for the entire duration of each confinement period and return for outpatient visits
• Willing and able to consume the entire high-calorie, high-fat breakfast meal in the designated timeframe required during fed study period
• Vital signs at both screening and at baseline within: heart rate: 50-90 beats per minute; systolic blood pressure: 100-130 mmHg; diastolic: 60-90 mmHg

Exclusion Criteria:

• Clinically relevant abnormal history, physical findings, ECG, or laboratory values at screening that could interfere with the objectives of the trial or safety of the volunteer, including any of the following:
• Lipid and/or liver function test results >1.25 times upper limit of normal or another clinical laboratory result judged clinically significant
• An international normalised ratio of >1.2 or a platelet count <150 x10^3/mL
• History of unexplained syncope
• Family history of unexplained sudden death or sudden death due to long QT syndrome
• QTcF interval >450 msec at screening
• Bundle branch block or another conduction abnormality during an ECG, other than mild first degree atrio-ventricular block, judged clinically significant
• Irregular rhythms during an ECG, other than sinus arrhythmia or occasional supraventricular ectopic beats, judged clinically significant
• T-wave configuration of insufficient quality for determination of QT interval, as assessed by ECG and judged clinically significant by the Investigator
• Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial or make study participation unnecessarily hazardous
• Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, hematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness
• Surgery (e.g. stomach bypass) or medical condition that might affect absorption, metabolism, or elimination of medicines
• Presence or history of severe adverse reaction to any drug and/or a history of skin reactions (rashes) to any drug
• Previous allergic response which involved hives, swelling, shortness of breath, or anaphylaxis
• Has used any over-the-counter medications, nutritional or dietary supplements, herbal preparations, or vitamins, except short courses of medication (such as acetaminophen), that could interfere with subject safety or the integrity of the trial data within 7 days prior to the first dose of medication
• Any prescription medication within 14 days prior to the first dose of study medication
• Participation in another clinical trial within 60 days prior to the first dose of study medication
• Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist
• Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily
• Unwilling or unable to comply with all protocol requirements
• Positive urine screen for drugs of abuse
• Positive for hepatitis B surface antigen, hepatitis C antibody or Human Immunodeficiency Virus at screening or previously treated for hepatitis B, hepatitis C, or Human Immunodeficiency Virus infection
• Donated blood or plasma within 30 days prior to the first dose of study medication
• Employee of the investigator site or any company involved in sponsoring, organizing, or conducting the trial, or immediate family of the employee

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment A; A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions	Drug: IX-01 caplets 1600 mg (4 x 400 mg), fasted; oral dose under fasted conditions
Experimental: Treatment B; A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions	Drug: IX-01 caplets 1600 mg (4 x 400 mg), fed; oral dose under fed conditions
Experimental: Treatment C; A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.	Drug: IX-01 aqueous dispersion 1600 mg (20 mL), fasted; oral dose under fasted conditions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic parameter peak plasma concentration of IX-01 (C max)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Pharmacokinetic parameter time of peak plasma concentration of IX-01 (t max)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Pharmacokinetic parameter terminal half-life (t 1/2)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Pharmacokinetic parameter elimination rate constant (K el)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Relative bioavailability of the caplet formulation of IX-01 compared with the aqueous dispersion formulation (fasted)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Pharmacokinetic parameter area under the concentration-time curve (AUC 0-inf)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
area under the concentration-time curve from 0 up to the time of last quantifiable concentration (AUC last)	Relative bioavailability of the caplet formulation of IX-01compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
The relative bioavailability of IX-01, as judged by AUC 0-inf (F rel)	Relative bioavailability of the caplet formulation of IX-01 compared with the aqueous dispersion formulation when administered in the fasted state	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Comparison of Maximum Plasma Concentration [Cmax] in fed versus fasted states	To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Comparison of Area Under the Curve [AUC] in fed versus fasted states	To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Comparison of Time to Maximum Plasma Concentration [Tmax] in fed versus fasted states	To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose
Comparison of the Area Under the Curve [AUC] in fed versus fasted states	To determine the effect of a high-fat meal on the pharmacokinetic profile of the IX-01 caplet formulation	pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety monitoring - adverse events, laboratory data, ECGs, vital signs	To monitor the safety and tolerability of IX-01	Day 0 to Day 21

Collaborators and Investigators

• Sponsor: Ixchelsis Limited

Study record dates

Study Major Dates

• Study Start: November 1, 2016
• Primary Completion (Actual): December 1, 2016
• Study Completion (Actual): December 1, 2016

Study Registration Dates

• First Submitted: October 24, 2016
• First Submitted That Met QC Criteria: November 9, 2016
• First Posted (Estimate): November 11, 2016

Study Record Updates

• Last Update Posted (Estimate): January 13, 2017
• Last Update Submitted That Met QC Criteria: January 12, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Other Study ID Numbers: IX-0106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO